Therapy Areas: Autoimmune
Kjems Named Chief Medical Officer at Ocelot Bio
20 April 2023 - - Lise Kjems, M.D., Ph.D., has joined US-based clinical-stage biopharmaceutical company Ocelot Bio, Inc as chief medical officer, the company said.

Dr. Kjems will oversee the clinical development efforts for Ocelot Bio's lead candidate, OCE-205, for the treatment of hepatorenal syndrome with acute kidney injury (HRS-AKI) and ascites.

Dr. Kjems succeeds founding chief scientific & medical officer, Stan Bukofzer, M.D., who will provide continued guidance to Ocelot Bio as a Strategic Advisor.

Dr. Kjems holds more than 20 years of experience in R&D across a breadth of therapeutic categories, including liver disease, endocrinology, rare disease, autoimmune, gastrointestinal and infectious disease.

Prior to joining Ocelot Bio, Dr. Kjems was the chief medical officer at Cyclo Therapeutics where she led its global program evaluating Trappsol Cyclo in Alzheimer's and rare disease.

Earlier in her career, Dr. Kjems was essential in bringing Albireo Pharma's drug Bylvay through its Phase 3 program in progressive familial intrahepatic cholestasis to FDA and EMA approvals, as well as launching pivotal Phase 3 trials for Bylvay in biliary atresia and Alagille syndrome.

She has also held various positions of increasing responsibility at Aldeyra Therapeutics, Intarcia Therapeutics, Ionis Pharmaceuticals, Johnson & Johnson and Novartis.

Dr. Kjems received her M.D. and her Ph.D. in physiology from the University of Copenhagen Medical Faculty Denmark.

She was an invited guest research fellow at the University of Southern California, Keck School of Medicine, and an industrial research fellow at Novo Nordisk A/S Bagsvaerd Denmark & University of Copenhagen.

Ocelot Bio is a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics designed to significantly improve outcomes for patients with liver disease.

The company's lead clinical candidate, OCE-205, is a peptide therapeutic with a mechanism of action designed to selectively target complications of portal hypertension, such as hepatorenal syndrome with acute kidney injury (HRS-AKI), a serious and life-threatening consequence of end-stage liver disease.

The company was founded by leading experts in peptide therapeutic development and is backed by a strong syndicate of investors including Venrock, RA Capital Management and Vivo Capital.
Login
Username:

Password: